HIV-1 capsid and viral DNA integration
mBio · 2024
DOI: 10.1128/mbio.00212-22 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift mBio, 2024. Verfasst von Richa Dwivedi und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Seropositivity, HIV Infections. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIDA NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
The human immunodeficiency virus type 1 (HIV-1) genome encodes 15 proteins that perform structural, enzymatic, regulatory, and accessory functions. The capsid protein (CA) is the primary structural protein of HIV-1 and plays multiple functions during infection. Early studies predicted that HIV-1 CA mainly protected and delivered the viral genome to the target cell. However, it is now well established that CA plays a critical role after the cellular entry steps of infection. During the early stages, CA promotes reverse transcription of the RNA genome into a DNA copy and the nuclear import/entry step of HIV-1 infection. Emerging evidence also supports the functional role of CA in the post-nuclear entry steps of infection, such as HIV-1 integration. During the late stages of infection, CA coordinates hexameric lattice formation for the assembly of immature virion. CA also regulates theformation of the mature capsid that encases the viral genome and associated factors in the infectious progeny virion. Because of these indispensable roles, HIV-1 CA has emerged as a new and validated target for antiviral drug development. Accordingly, the first CA-targeting drug, lenacapavir (GS-6207), was recently approved to treat certain HIV-1-infected individuals whose viral load cannot be controlled by other antiviral drugs. Still, new and superior CA inhibitors are needed to qualify as part of the front-line antiviral therapy regimens for all infected individuals. The development of such inhibitors requires a clear understanding of CA’s role in HIV-1 infection. In this review, we will describe CA’s role during the early stages of HIV-1 infection, with particular emphasis on post-nuclear entry steps. IMPORTANCE HIV-1 capsid protein (CA)—independently or by recruiting host factors—mediates several key steps of virus replication in the cytoplasm and nucleus of the target cell. Research in the recent years have established that CA is multifunctional and genetically fragile of all the HIV-1 proteins. Accordingly, CA has emerged as a validated and high priority therapeutic target, and the first CA-targeting antiviral drug was recently approved for treating multi-drug resistant HIV-1 infection. However, development of next generation CA inhibitors depends on a better understanding of CA’s known roles, as well as probing of CA’s novel roles, in HIV-1 replication. In this timely review, we present an updated overview of the current state of our understanding of CA’s multifunctional role in HIV-1 replication—with a special emphasis on CA’s newfound post-nuclear roles, highlight the pressing knowledge gaps, and discuss directions for future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Center for AIDS Health Disparities Research, Meharry Medical College, Nashville, Tennessee, USA.
- Department of Microbiology, Immunology, and Physiology, Meharry Medical College, Nashville, Tennessee, USA.
- Department of Biochemistry, Cancer Biology, Neuroscience and Pharmacology, Meharry Medical College, Nashville, Tennessee, USA.
- Department of Biological Sciences, Sunandan Divatia School of Science, NMIMS (Deemed to be) University, Mumbai, Maharashtra, India.
ORCID-Profile: Richa Dwivedi, Muthukumar Balasubramaniam, Chandravanu Dash
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- NIMHD NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Dwivedi, R., Prakash, P., Kumbhar, B. V., Balasubramaniam, M., & Dash, C. (2024). HIV-1 capsid and viral DNA integration. mBio. https://doi.org/10.1128/mbio.00212-22
Vancouver
Dwivedi R, Prakash P, Kumbhar BV, Balasubramaniam M, Dash C. HIV-1 capsid and viral DNA integration. mBio. 2024. doi:10.1128/mbio.00212-22
BibTeX
@article{Dwivedi2024,
author = {Dwivedi, Richa and Prakash, Prem and Kumbhar, Bajarang Vasant and Balasubramaniam, Muthukumar and Dash, Chandravanu},
title = {HIV-1 capsid and viral DNA integration},
journal = {mBio},
year = {2024},
doi = {10.1128/mbio.00212-22}
}
EUVIMED